Fosamax and Osteonecrosis of the Jaw: Understanding the Link

Latest update (2026-05)

FDA enforcement record (Ongoing): This recall is being conducted due to out of specification assay results in a limited number of bottles that were stored on side. [source]

From General Health Information to Targeted Risk Assessment

For decades, general health and science information has served as the primary conduit for public understanding of medical conditions and treatments. This legacy framework, rooted in broad educational outreach, effectively disseminated foundational knowledge about bone health, metabolic disorders, and therapeutic interventions. Within this context, audiences became familiar with the role of bisphosphonates and other agents in managing osteoporosis, as well as the importance of routine dental care as part of overall wellness. However, as clinical experience and post-market surveillance matured, a more specialized concern emerged: the association between certain bone-modifying drugs and osteonecrosis of the jaw. This shifted the focus from general health maintenance to a targeted risk assessment for specific patient populations. The transition from a broad informational heritage to a focused occupational exposure concern is particularly relevant in mass production settings, where workers may encounter these pharmaceutical agents during manufacturing, handling, or disposal. In such environments, the potential for unintended exposure—whether through inhalation, dermal contact, or ingestion—necessitates a reevaluation of standard safety protocols. Thus, the general health context now serves as a foundation for understanding how occupational exposure to these compounds may elevate risk, requiring specialized monitoring and preventive measures distinct from patient-centered care.

Bridging General Knowledge to Specific Drug Risks

Building on the general understanding of bone health and bisphosphonates, this section focuses specifically on Fosamax (alendronate) and its association with osteonecrosis of the jaw (ONJ). Fosamax is a bisphosphonate medication prescribed for conditions such as postmenopausal osteoporosis. A known adverse effect associated with bisphosphonate use, including Fosamax, is osteonecrosis of the jaw. ONJ involves the death of jawbone tissue, which can occur spontaneously but is often linked to dental procedures or local infections. This narrative examines the clinical presentation, mechanistic pathways, risk factors, and causation considerations related to Fosamax and ONJ, based on provided evidence.

Clinical Presentation and Diagnosis of ONJ

Osteonecrosis of the jaw presents as exposed, non-healing bone in the maxillofacial region, often following tooth extraction or local infection with delayed healing. The condition has been reported in patients taking bisphosphonates, including Fosamax (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=14e931fd-2c5f-4d90-b7db-5980706f4a56). Histomorphologic analyses of jawbone in animal models show nonvital bone with empty osteocytic lacunae, surrounded by amorphous material and inflammatory infiltrate, with rounded bone margins and no cells (https://pubmed.ncbi.nlm.nih.gov/41758628). These findings align with the diagnosis of ONJ, which can be confirmed through clinical examination and imaging.

Fosamax Pharmacology and Reported Adverse Effects

Fosamax belongs to the bisphosphonate class, which inhibits bone resorption by suppressing osteoclast activity. While effective for osteoporosis, this suppression can impair normal bone turnover and healing. The time to onset of ONJ symptoms after starting Fosamax varies from one day to several months (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=14e931fd-2c5f-4d90-b7db-5980706f4a56). In placebo-controlled clinical studies, the percentages of patients with these symptoms were similar in the Fosamax and placebo groups, suggesting that ONJ is a rare adverse event (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=14e931fd-2c5f-4d90-b7db-5980706f4a56). Discontinuation of Fosamax is recommended if severe symptoms develop, and most patients experience relief after stopping. However, a subset of patients may have recurrence of symptoms when rechallenged with the same drug or another bisphosphonate (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=14e931fd-2c5f-4d90-b7db-5980706f4a56).

Mechanistic Pathways Linking Fosamax to ONJ

The jawbone has unique structural and metabolic characteristics that may predispose it to bisphosphonate-related complications. Multiscale characterization of jawbone provides comprehensive information to understand jawbone-specific responses to bone-related complications, including bisphosphonate-related ONJ (https://pubmed.ncbi.nlm.nih.gov/40345077). Bisphosphonates like Fosamax accumulate in bone and inhibit osteoclast-mediated remodeling, which can lead to microdamage accumulation and impaired healing. In animal studies, bisphosphonate treatment resulted in nonvital bone with empty osteocytic lacunae and inflammatory infiltrate, regardless of whether the socket was filled with leukocyte- and platelet-rich fibrin (L-PRF), suggesting that L-PRF did not prevent ONJ occurrence (https://pubmed.ncbi.nlm.nih.gov/41758628). This indicates that the drug's effect on bone turnover is a key mechanistic factor.

Risk Factors and Adequacy of Warnings

Known risk factors for ONJ include invasive dental procedures (e.g., tooth extraction, dental implants, boney surgery), diagnosis of cancer, concomitant therapies (e.g., chemotherapy, corticosteroids, angiogenesis inhibitors), poor oral hygiene, and co-morbid disorders (e.g., periodontal disease, anemia, coagulopathy, infection, ill-fitting dentures) (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=10307e7e-9a84-4aa1-8c5c-4b209cffe4d1). The risk of ONJ may increase with longer duration of bisphosphonate exposure (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=10307e7e-9a84-4aa1-8c5c-4b209cffe4d1). For patients requiring invasive dental procedures, discontinuation of bisphosphonate treatment may reduce the risk for ONJ (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=10307e7e-9a84-4aa1-8c5c-4b209cffe4d1). The prescribing information for Fosamax includes warnings about ONJ, noting that it can occur spontaneously or be associated with dental procedures. However, the adequacy of these warnings may be questioned given that ONJ is a serious condition that can lead to significant morbidity. The label advises discontinuation if severe symptoms develop and notes that most patients improve after stopping the drug (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=14e931fd-2c5f-4d90-b7db-5980706f4a56). Yet, the recurrence of symptoms upon rechallenge highlights the need for careful monitoring and patient education.

Causation Considerations and Timeline

Causation between Fosamax and ONJ is supported by the temporal relationship between drug exposure and symptom onset, which can range from one day to several months (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=14e931fd-2c5f-4d90-b7db-5980706f4a56). The biological plausibility is grounded in bisphosphonate pharmacology, which suppresses bone turnover and impairs healing. The evidence from animal studies showing nonvital bone after bisphosphonate treatment further supports causation (https://pubmed.ncbi.nlm.nih.gov/41758628). Additionally, a retrospective case series in cats highlights that bisphosphonate-related ONJ, though rare, is a recognized entity in both human and veterinary medicine (https://pubmed.ncbi.nlm.nih.gov/39247125). For affected patients, establishing causation involves documenting the timeline of Fosamax use, any dental procedures, and the development of ONJ symptoms. The presence of other risk factors, such as cancer or corticosteroid use, may complicate the assessment but does not negate the potential role of Fosamax.

Important Notice

This page is for educational and informational purposes only. It does not provide medical diagnosis, treatment, or legal advice. Consult licensed clinicians and qualified attorneys for case-specific decisions.

Frequently Asked Questions

What is osteonecrosis of the jaw (ONJ)?

Osteonecrosis of the jaw (ONJ) is a condition characterized by exposed, non-healing bone in the jaw, often occurring after dental procedures or spontaneously. It has been associated with bisphosphonate medications like Fosamax.

How does Fosamax cause ONJ?

Fosamax suppresses bone turnover by inhibiting osteoclast activity, which can lead to microdamage accumulation and impaired healing in the jawbone. This mechanism is supported by animal studies showing nonvital bone after bisphosphonate treatment (https://pubmed.ncbi.nlm.nih.gov/41758628).

What are the risk factors for developing ONJ while taking Fosamax?

Risk factors include invasive dental procedures, longer duration of bisphosphonate use, cancer, chemotherapy, corticosteroids, poor oral hygiene, and co-morbid conditions like periodontal disease (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=10307e7e-9a84-4aa1-8c5c-4b209cffe4d1).

Does submitting information create an attorney-client relationship?

No. Submission requests an initial records screening only and does not create an attorney-client relationship.

Information Registry: individuals with documented Fosamax exposure and a confirmed Osteonecrosis of the Jaw diagnosis may request an independent eligibility review. [Begin Assessment]

References

Request a Free Case Review

This page is for educational and informational purposes only and is not medical or legal advice. Consult a licensed professional for case-specific guidance.

Community Resource & Benefit Desk

Request archival records or inquire about member-exclusive transition and benefit programs.